A systematic review and meta-analysis suggested that untreated white coat hypertension (WCH, isolated elevated office blood pressure [BP]), but not treated white coat effect (WCE, treated WCH), is associated with an increased risk for cardiovascular events and all-cause mortality. The analysis included 27 observational studies, comprising 25 786 participants with untreated WCH or treated WCE and 38 487 with normal BP followed for a mean of 3 to 19 years. Compared with normotension, untreated WCH was associated with an increased risk for cardiovascular events (hazard ratio [HR], 1.36), all-cause mortality (HR, 1.33), and cardiovascular mortality (HR, 2.09); the risk of WCH was attenuated in studies that included stroke in the definition of cardiovascular events (HR, 1.26). No significant increased risk was found with treated WCE. The findings persisted across several sensitivity analyses although are not consistent with several early studies. The analysis supports guidelines recommending out-of-office BP monitoring. Source: https://annals.org/

hyangiu

Recent Posts

Global Study of Stroke Risk Factors

A study revealed that stroke remains a major global health challenge, influenced by numerous risk…

2 days ago

Antidepressants Effective and Safe in Older Adults with Anxiety

A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…

3 days ago

Geographical Variation in Lipoprotein (a) Levels Among CHD Patients

A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…

2 weeks ago

The Science and Skepticism around Seed Oils

A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…

3 weeks ago

Bedtime Antihypertensive Comparable to Morning Use

A Canadian study of adults with high blood pressure (BP) found no difference in health…

4 weeks ago

Obicetrapib Effective and Safe in Improving Lipids

Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…

1 month ago

This website uses cookies.